In the last three months, 14 analysts have published ratings on Edwards Lifesciences EW, offering a diverse range of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 3 | 5 | 1 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 1 | 0 | 0 |
| 2M Ago | 1 | 1 | 0 | 1 | 0 |
| 3M Ago | 3 | 1 | 4 | 0 | 0 |
Analysts have set 12-month price targets for Edwards Lifesciences, revealing an average target of $76.71, a high estimate of $85.00, and a low estimate of $57.00. This current average represents a 10.36% decrease from the previous average price target of $85.58.
Exploring Analyst Ratings: An In-Depth Overview
In examining recent analyst actions, we gain insights into how financial experts perceive Edwards Lifesciences. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Shagun Singh | RBC Capital | Raises | Outperform | $82.00 | $80.00 |
| Vijay Kumar | Evercore ISI Group | Lowers | In-Line | $77.00 | $80.00 |
| Richard Newitter | Truist Securities | Raises | Buy | $84.00 | $78.00 |
| Richard Newitter | Truist Securities | Raises | Buy | $78.00 | $76.00 |
| Patrick Wood | Morgan Stanley | Lowers | Overweight | $80.00 | $102.00 |
| Mike Polark | Wolfe Research | Announces | Underperform | $57.00 | - |
| Rick Wise | Stifel | Lowers | Hold | $70.00 | $87.00 |
| Anthony Petrone | Mizuho | Lowers | Buy | $85.00 | $90.00 |
| Richard Newitter | Truist Securities | Lowers | Buy | $76.00 | $83.00 |
| Shagun Singh | RBC Capital | Lowers | Outperform | $82.00 | $86.00 |
| Adam Maeder | Piper Sandler | Lowers | Neutral | $68.00 | $83.00 |
| Joanne Wuensch | Citigroup | Lowers | Buy | $85.00 | $94.00 |
| Larry Biegelsen | Wells Fargo | Lowers | Equal-Weight | $75.00 | $88.00 |
| Mike Kratky | Leerink Partners | Announces | Market Perform | $75.00 | - |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Edwards Lifesciences. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Edwards Lifesciences compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Edwards Lifesciences's stock. This comparison reveals trends in analysts' expectations over time.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Edwards Lifesciences's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Edwards Lifesciences analyst ratings.
Unveiling the Story Behind Edwards Lifesciences
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, catheters, and monitoring systems used to measure a patient's heart function during surgery. The firm derives about 55% of its total sales from outside the U.S.
Edwards Lifesciences's Financial Performance
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Edwards Lifesciences displayed positive results in 3 months. As of 30 September, 2023, the company achieved a solid revenue growth rate of approximately 12.27%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Edwards Lifesciences's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 25.99% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 5.91%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Edwards Lifesciences's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 4.19% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.1.
Analyst Ratings: Simplified
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
